APOA1 Gene Amyloidosis Familial Visceral Genetic Test
Are you concerned about familial visceral amyloidosis? DNA Labs UAE offers the APOA1 Gene Amyloidosis Familial Visceral Genetic Test at a cost of AED 4400.0. This test utilizes next-generation sequencing (NGS) technology to analyze the APOA1 gene for genetic mutations associated with familial visceral amyloidosis.
Test Components
- Price: AED 4400.0
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Metabolic Disorders
- Doctor: General Physician
- Test Department: Genetics
Pre Test Information
Prior to undergoing the APOA1 Gene Amyloidosis Familial Visceral Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected with familial visceral amyloidosis.
Test Details
Familial visceral amyloidosis is a rare genetic disorder characterized by the buildup of abnormal amyloid proteins in organs such as the liver, kidneys, and heart. The APOA1 gene provides instructions for producing the apolipoprotein A1 (APOA1) protein, which is a major component of high-density lipoprotein (HDL) cholesterol. Mutations in the APOA1 gene can disrupt the normal function of the APOA1 protein, leading to the accumulation of amyloid deposits in the organs.
The APOA1 Gene Amyloidosis Familial Visceral Genetic Test utilizes NGS technology to analyze the entire coding region of the APOA1 gene. This allows for the identification of any genetic mutations or variants associated with familial visceral amyloidosis. The test can detect both known and novel mutations, providing valuable information for accurate diagnosis, prognosis, and genetic counseling.
For the test, a blood or saliva sample is typically collected. The DNA is then extracted and sequenced using NGS technology. The resulting genetic data is compared to a reference sequence to identify any genetic variations or mutations. The test results can confirm a diagnosis of familial visceral amyloidosis and guide appropriate management and treatment strategies.
In addition to diagnosis, genetic testing can also be used to identify at-risk family members who may benefit from early detection and intervention. It is important to note that the interpretation of genetic testing results should be done by a qualified healthcare professional or genetic counselor, as the implications may extend to the individual and their family members.
| Test Name | APOA1 Gene Amyloidosis familial visceral Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Metabolic Disorders |
| Doctor | General Physician |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for APOA1 Gene Amyloidosis, familial visceral NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with Amyloidosis, familial visceral |
| Test Details |
APOA1 gene amyloidosis, familial visceral NGS genetic test is a diagnostic test that uses next-generation sequencing (NGS) technology to analyze the APOA1 gene for genetic mutations associated with familial visceral amyloidosis. Familial visceral amyloidosis is a rare genetic disorder characterized by the buildup of abnormal amyloid proteins in various organs, including the liver, kidneys, and heart. These amyloid deposits can lead to organ dysfunction and failure. The APOA1 gene provides instructions for producing the apolipoprotein A1 (APOA1) protein, which is a major component of high-density lipoprotein (HDL) cholesterol, also known as “good cholesterol.” Mutations in the APOA1 gene can disrupt the normal function of the APOA1 protein, leading to the accumulation of amyloid deposits in the organs. The NGS genetic test analyzes the entire coding region of the APOA1 gene to identify any genetic mutations or variants that may be associated with familial visceral amyloidosis. This test can detect both known and novel mutations, providing valuable information for accurate diagnosis, prognosis, and genetic counseling. The test is typically performed using a blood or saliva sample, and the DNA is extracted and sequenced using NGS technology. The resulting genetic data is then compared to a reference sequence to identify any genetic variations or mutations. The results of the test can help confirm a diagnosis of familial visceral amyloidosis and guide appropriate management and treatment strategies. Additionally, genetic testing can also be used to identify at-risk family members who may benefit from early detection and intervention. It is important to note that genetic testing for familial visceral amyloidosis should be interpreted by a qualified healthcare professional or genetic counselor, as the results may have implications for the individual and their family members. |
